RxDoctor Payments DataLook up a doctor →

Lindsay Ackerman, MD

Dermatology · Phoenix, AZNPI 1609900299

Payments from drug & device makers

$7,404,689in general payments, 2019–2025

Across 3,131 payments — averaging $2364.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.9M
  • UCB SA$1.6M
  • Incyte Corporation$1.4M
  • Eli Lilly$494K
  • E.r. Squibb & Sons, L.L.C.$342K
  • Lilly USA, LLC$317K
  • plus $1.4M from 46 others
$10,365in research payments, 2019–2025

Across 12 payments — averaging $863.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$10K
  • Eli Lilly$107

What the payments were for

  • Consulting fees$374,09724%
  • Speaking & faculty fees$1,076,63668%
  • Travel & lodging$95,2346%
  • Food & beverage$33,8722%
  • Education$6100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,404,689 in reported general payments places this provider in the 95th percentile of 305 dermatology providers in Arizona.

See all dermatology providers in Arizona

Medicare billing

Part B allowed, 2024
$380,658
Medicare patients
861
Services billed
6,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib44$307,069
Dupixent PenDupilumab46$183,639
Bimzelx AutoinjectorBimekizumab-Bkzx11$176,280
RemicadeInfliximab13$166,981
SotyktuDeucravacitinib22$147,512
OtezlaApremilast24$117,040
Taltz AutoinjectorIxekizumab12$85,772
Dupixent SyringeDupilumab11$48,570
Acitretin17$5,214
Clobetasol Propionate78$3,522
Triamcinolone Acetonide224$2,896
Dapsone21$2,431
Doxycycline Hyclate58$2,328
Ketoconazole124$2,161
ValacyclovirValacyclovir Hcl67$1,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,891,015$307,06944 claims
Johnson & JohnsonRemicade$88,357$166,98113 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$341,992$147,51222 claims
AmgenOtezla$113,754$117,04024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 305 dermatology providers in Arizona.

Other dermatology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →